方拓生物是一家基因治疗药物研发商,汇聚了中美两地具有丰富创新基因药物研发、生产、注册、临床研究管理经验的专业人员,聚焦罕见病及慢性疾病领域,致力于研发和生产高质量的、患者可支付的重组腺相关病毒(rAAV)载体基因治疗产品,以满足全球遗传性和慢性病患者远未被满足的临床治疗需求。今日方拓生物港交所递交招股书。
Source Link方拓生物是一家基因治疗药物研发商,汇聚了中美两地具有丰富创新基因药物研发、生产、注册、临床研究管理经验的专业人员,聚焦罕见病及慢性疾病领域,致力于研发和生产高质量的、患者可支付的重组腺相关病毒(rAAV)载体基因治疗产品,以满足全球遗传性和慢性病患者远未被满足的临床治疗需求。今日方拓生物港交所递交招股书。
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.